Media contact

Proposed by Italy in February 2019, the resolution is now being sponsored by ten countries: Italy, Greece, Malaysia, Portugal, Serbia, Slovenia, South Africa, Spain, Turkey, and Uganda. If passed, it would be a major step towards improving affordable prices for all essential medical tools worldwide. Today, a lack of transparency around what different countries pay for medicines, and the actual cost of researching, developing and manufacturing a particular medicine, allows pharmaceutical corporations to charge exorbitant and arbitrary prices.

MSF protests at J&J’s annual shareholders meeting to demand a say in how lifesaving tuberculosis drug developed with considerable joint efforts, including public funding and MSF operational research, will be made available and affordable.

Medical humanitarian organisation uses ‘Humanitarian Mechanism’ programme to access affordable versions of pneumonia vaccine to protect refugee children in Greece against the number one childhood killer worldwide

Most recent Priority Review Voucher is a reminder of why Congress should reform the US government program to only reward companies for developing new and affordable drugs and vaccines for neglected diseases

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug bedaquiline.

MSF welcomes new WHO treatment guidelines that recommend drug-resistant tuberculosis be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.

The appeal – filed by six organisations – states that the EPO should revoke Gilead’s patent on key hepatitis C drug sofosbuvir because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.

MSF criticises pharma for dragging feet on developing HIV drugs for children.